Donaldson R M, Williams L A, Lee E H
National Heart Hospital, London, England.
Am J Cardiol. 1988 Feb 10;61(5):49C-51C. doi: 10.1016/0002-9149(88)90485-7.
Beta-adrenoceptor blockade is an effective treatment for ischemic heart disease and hypertension, but the more widespread use of beta antagonists is limited by their bronchoconstrictor, vasoconstrictor and negative inotropic properties. Celiprolol has been shown in preclinical studies to be a beta 1-selective antagonist with bronchosparing and vasodilating properties, but without any cardiodepressant effect. This has been confirmed by clinical studies undertaken to date. The aim of the present study was to examine the acute effects of intravenous celiprolol on the cardiac hemodynamics of patients pretreated with oral atenolol.
β-肾上腺素能受体阻滞剂是治疗缺血性心脏病和高血压的有效药物,但β-拮抗剂更广泛的应用受到其支气管收缩、血管收缩和负性肌力特性的限制。在临床前研究中已表明,塞利洛尔是一种具有支气管保护和血管舒张特性的β1选择性拮抗剂,但无任何心脏抑制作用。迄今为止的临床研究已证实了这一点。本研究的目的是探讨静脉注射塞利洛尔对口服阿替洛尔预处理患者心脏血流动力学的急性影响。